Date: 2018-10-02
Type of information: Production agreement
Compound: Natural Killer (NK) cells
Company: Cytosen Therapeutics (USA - TX) KBI Biopharma (USA - NC)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: bioproduction - manufacturing
Action mechanism: cell therapy/immunotherapy product
Disease:
Details:
- • On October 2, 2018, CytoSen Therapeutics and KBI Biopharma announced a strategic partnership to manufacture therapeutic Natural Killer (NK) cells using a proprietary and scalable, closed system manufacturing process. As part of the initial collaboration, KBI will manufacture the NK cell product in its The Woodlands, Texas facility for CytoSen’s planned Phase 2 trial evaluating lead candidate CSTD002-NK in high risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), expected to begin the first half of 2019. KBI will also manufacture CytoSen’s proprietary nanoparticles used in the expansion of the NK cell product.
Financial terms:
Latest news:
Is general: Yes
